Could a single injection fix early hip arthritis?
NCT ID NCT05276011
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental injection called TG-C for people with early hip osteoarthritis. The injection contains cells that release a growth factor to help repair damaged cartilage. 255 adults will receive either TG-C or a placebo, and researchers will track pain and hip function for 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TG-C (TissueGene-C) – a single injection of cells that release a growth factor to help repair cartilage
What this could lead to
If it works, this could lead to a non-surgical treatment that reduces hip pain and delays or prevents the need for hip replacement.
What could go wrong
This is an early Phase 2 trial with only 255 people, so results may not apply to everyone. The injection is new and long-term safety is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEGENERATIVE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••